**Core tip:** Gastrointestinal angiodysplasias (GIADs) are the most frequent vascular malformations. They cause 10% of all gastrointestinal bleeding and 50% of small bowel bleeding cases. In most patients, they manifest with frequent bleeding episodes, requiring expensive treatments and disturbing patient's quality of life. In this review, we summarize the main aspects related to epidemiology, risk factors and pathophysiology of GIADs. The diagnostic challenge of causality and the efficiency of different treatment modalities available are critically discussed. A novel classification of GIADs based on endoscopic characteristics is proposed and future research directions that may improve diagnostic and therapeutic results will be highlighted.

INTRODUCTION
============

Gastrointestinal angiodysplasias (GIADs), also called angioectasias, are vascular malformations composed of dilated and tortuous arterial or venous capillaries, which are usually smaller than 5 mm in diameter and located in the mucosal and submucosal layers of the gastrointestinal tract. They are part of a group of vascular aberrations, some of which are hereditary, such as hereditary hemorrhagic telangiectasia and others are acquired, such as gastric antral vascular ectasia, radiation-induced vascular ectasia, Dieulafoy's lesion and GIADs\[[@B1]\]. GIADs are the most frequent vascular lesions. They are responsible for approximately 10% of gastrointestinal bleeding (GIB) cases and are difficult to diagnose, particularly those placed in the small bowel. Current treatment is very diverse (since therapeutic guidelines have not been established) and bleeding recurrences remain frequent in most cases\[[@B2]\].

In this review, we will address the epidemiology and pathophysiology of the lesions and critically discuss the status in the diagnosis and treatment of GIADs with special emphasis on small bowel angiodysplasias (SBADs). In addition, we will propose a simple classification of angiodysplasias based on their endoscopic characteristics and will discuss the clinical manifestations and bleeding recurrence frequency probably associated to different types of angiodysplasias. Finally, we will point out some aspects that need to be clarified in future research studies.

EPIDEMIOLOGY
============

The prevalence of GIADs is difficult to determine because most of them are asymptomatic. They are incidentally found in 1% to 5% of patients who underwent endoscopic studies and remain asymptomatic in a period of 3 years of follow-up\[[@B3],[@B4]\]. These vascular lesions are mostly detected in patients older than 60 years, so it is thought that they have a degenerative component\[[@B4],[@B5]\]. This association may indicate that its globally incidence is increasing, as the population is becoming older, particularly in developed countries.

GIADs can be found in any segment of the digestive tract. Before the introduction of the video capsule endoscopy (VCE) and the device-assisted enteroscopy (DAE), it was thought that GIADs occurred more frequently in the caecum and ascending colon. In recent studies, in which the entire digestive tract is reviewed, it has been found that these lesions are more frequent in the small bowel (57%-80%), particularly in the proximal segment, followed by the colon (44%) and the stomach (32%)\[[@B6],[@B7]\]. These lesions are located in more than one segment of the digestive tract in 60% of cases\[[@B8]\]. It is reported that they can be responsible of 4% to 7% of nonvariceal upper GIB cases\[[@B8],[@B9]\]. Moreover, 77% of patients with GIADs experience at least one episode of visible bleeding (hematemesis or melena) with or without hemodynamic instability, while the remaining ones have transfusion-dependent or intravenous iron infusion-dependent chronic anemia due to occult bleeding. In the colon, 3% to 40% of the bleeding cases are caused by GIADs\[[@B10],[@B11]\]. In the 2% of such cases, bleeding may be a cause of death, particularly in elderly patients presenting cardiovascular disease or chronic renal failure (CRF)\[[@B12]\].

RISK FACTORS
============

Several morbid conditions associated with the presence of bleeding GIADs have been identified. The causal relationship between such morbid conditions and the GIADs is difficult to elucidate, since they could be confounding factors because angiodysplasias are more frequent in elderly individuals. In addition, the use of anticoagulant, antithrombotic and platelet antiaggregant drugs are only involved in the induction of bleeding from preexistent vascular lesions.

The association between bleeding GIADs and aortic stenosis has been extensively described. This condition is known as Heyde\'s disease\[[@B13]\]. Similar association has not been found in other valvular heart diseases\[[@B14]\]. The most accepted explanation of this association is that aortic stenosis could cause the destruction of high-molecular-weight von Willebrand factor (vWF) multimers, leading to acquired von Willebrand disease with a tendency to bleed\[[@B15]\]. Improvement of anemia and reduction or disappearance of bleeding recurrences from GIADs have been described in many patients who underwent aortic valve replacement\[[@B16],[@B17]\]. However, this issue has not been conclusively resolved and currently, the indication of this surgical treatment for GIADs is controversial\[[@B18]\]. The association of bleeding SBADs and low-flow left ventricular assist devices implantation in patients with advanced heart failure has been recently reported. A similar pathogenic mechanism that was described for aortic stenosis, may be involved in this association\[[@B19]\].

On the other hand, GIADs are very common in patients with CRF, and their incidence is further increased by the duration and severity of the renal disease\[[@B20]\]. GIADs are responsible for 19% to 32% of episodes of lower GIB in patients with CRF compared to 5% to 6%, observed in the general population. The most constant factor in the induction of bleeding in CRF patients is platelet dysfunction, which include impaired platelet adhesion and aggregation, produced by extrinsic and intrinsic factors\[[@B21],[@B22]\]. It is not clear if the CRF induces generation of vascular lesions, or if only induces the bleeding due to the hemorrhagic diathesis or both. The risk of bleeding is even greater in patients undergoing hemodialysis where the use of anticoagulants is frequent and uremia is higher\[[@B23]\]. Recently, a significant association between SBADs and other comorbidities such as chronic obstructive pulmonary disease, venous thromboembolism, cardiovascular disease, and liver cirrhosis has been found\[[@B24],[@B25]\] (Table [1](#T1){ref-type="table"}).

###### 

Risk factors for gastrointestinal angiodysplasias

  **Risk factors for gastrointestinal angiodysplasias**
  --------------------------------------------------------
  1 Age \> 60 yr
  2 Chronic obstructive pulmonary disease
  3 Aortic stenosis (Heyde´s disease)
  4 Low-flow left ventricular assist devices
  5 Von Willebrand disease
  6 Venous thromboembolism
  7 Ischemic heart disease
  8 Liver cirrhosis
  9 Drugs[1](#T1FN1){ref-type="table-fn"}: Anti-platelet
  Anti-coagulant
  Anti-thrombotic

Related with bleeding induction.

PATHOPHYSIOLOGY
===============

The pathophysiology of GIADs is not precisely known. Currently, several theories have been proposed, which have different points of contact among them:

Intestinal smooth muscle contraction
------------------------------------

it has been suggested that a repeated and sustained increase in smooth muscle contractions of the muscularis propria would cause intermittent obstruction of the sub mucosal veins of the intestinal wall, which would lead to capillary congestion and insufficiency of the precapillary sphincters with the formation of arteriovenous collaterals\[[@B26]\]. This theory might explain the presence of these lesions in the cecum and the ascending colon, where the intraluminal pressure is higher and the walls are thinner than in other segments of the digestive tract. However, it does not explain the presence of such lesions in other segments thereof such as the stomach.

Mucosal ischemia and chronic hypoxemia
--------------------------------------

It has been proposed that muscular contractions of the muscularis propria would trigger a chronic hypoxemia, which would lead to angiogenesis mediated by chemical agents, of which the most important is the vascular endothelial growth factor (VEGF)\[[@B27]\]. This chemical mediator is released in response to tissue hypoxia and is a central active agent in the early stages of angiogenesis\[[@B28]\]. A similar mechanism could also explain the association between GIADs and aortic stenosis\[[@B29]\].

Induction of angiogenesis
-------------------------

The proliferation of blood vessels (a process known as angiogenesis) could be induced by the primary or secondary reduction of high-molecular-weight vWF multimers, which increases VEGF-dependent angiogenesis and reduces platelet adhesion and aggregation. Finally, a decrease in platelet adhesion and aggregation by drug-induced inhibition of erythropoietin has been observed in CRF\[[@B30]\] (Figure [1](#F1){ref-type="fig"}).

![Pathogenesis of gastrointestinal angiodysplasias. VEGF: Vascular endothelial growth factor; vWF: Von Willebrand factor; CRF: Chronic renal failure.](WJG-25-2549-g001){#F1}

In support of these angiogenesis theories, elevated tissue expression and serum VEGF levels have been found in patients with GIADs compared to normal subjects\[[@B30],[@B31]\]. Another recent study has found a significant association between GIADs and abnormality of the metabolic pathway of angiopoietins suggesting the potential role of angiopoietin-1 (Ang-1) and Ang-2 in the development of vascular lesions\[[@B32]\].

BLEEDING CAUSALITY
==================

The finding of non-bleeding GIADs by endoscopy in patients with GIB confronts the clinician with the dilemma of the bleeding responsibility of such lesions. Most authors suggest that in the absence of other evident actively bleeding source, the responsibility of GIAD may be accepted\[[@B33]\]. However, this assumption may be reasonably questioned. On the other hand, clinical or endoscopic systems for estimating probability of bleeding causality of GIADs have not been assessed. This issue is complicated by the fact that a significant number of GIADs are asymptomatic and most of them have a very low probability of bleeding in a period of 3 years after detection\[[@B4],[@B34]\].

SMALL BOWEL ANGIODYSPLASIAS
===========================

GIADs are more common in the small bowel than in other segments of the digestive tract (57%-80%), where they are the cause of 5% of all GIB cases. Before the 2000s, the detection of SBADs was very difficult, since the available diagnostic procedures \[scintigraphy, simple angiography, computed tomography (CT), magnetic resonance imaging (MRI)\] had low sensitivity and specificity\[[@B35],[@B36]\], therefore multiple diagnostic procedures and hospitalizations were usually performed to these patients before diagnosis, thus increasing the costs of medical care\[[@B37]\]. CT or MRI angiography moderately improved these numbers\[[@B38]\]. Push enteroscopy, which was the only available deep endoscopic method, allowed the revision of only the proximal third of the small bowel\[[@B39]\]. In the last decade, with the introduction of VCE and DAE, the detection of SBADs as the cause of GIB has increased\[[@B40]-[@B42]\]. There are three types of DAE: Double-balloon, single-balloon and spiral enteroscopy, which allow the complete or partial revision of SB through retrograde and /or anterograde access\[[@B43]-[@B45]\]. These methods are as efficacious as VCE for SBADs detection\[[@B46],[@B47]\] and have the advantage that allow the application of endoscopic therapies to vascular lesions. However, they are invasive and expensive procedures, requiring sedation administration and expertise operating personal; therefore, they are reserved exclusively for endoscopic treatment of lesions, leaving the VCE as first-line diagnostic procedure in obscure GIB (OGIB) patients.

Multiple studies have reported that OGIB is the most frequent indication of VCE, representing from 70% to 75% of cases\[[@B48],[@B49]\]. The presence of GIADs has been demonstrated in about 50% to 60% of such cases\[[@B50]-[@B52]\]. In 40% to 60% of cases, SBADs are multiple and 20% coexists with lesions located outside the small bowel, particularly in the colon\[[@B53]\]. From 50% to 80% of the lesions is located in the jejunum and duodenum, 5% to 20% in the ileum and 60% of patients is over 60 years of age\[[@B54]\]. Despite the achievement of recent advances in the diagnosis of SBADs, some important points must be taken into account for interpretation of procedure results. (1) Limitations of the VCE in detection of lesions due to accelerated peristalsis, presence of intestinal detritus or the concealment of lesions by the mucosal folds; (2) The incomplete revision of small bowel with VCE and DAE, which is observed in 10%-16% and 40%-50% of cases respectively\[[@B55]\]; (3) Observer experience in the recognition of lesions. Detection of GIADs is usually easy when they present as typical bright red spots; however, mucosal erosions or erythema may be confounded with GIADs and conversely, pale red angiodysplasias may be unnoticed\[[@B56],[@B57]\].

NATURAL HISTORY
===============

The bleeding recurrence of SBADs is greater than that of the colon and stomach\[[@B58]\]. In a retrospective study that involved 56 patients with SBADs, the bleeding recurrence occurred in 80% of the cases, the first bleeding episode was observed in an average of 10.7 mo of follow-up, 70% of the cases required transfusions, 67% hospital readmissions and 50% endoscopic, pharmacological or surgical therapy. Deaths related to bleeding occurred in 3.5% of cases. Multiple lesions and cardiovascular diseases were independent predictors of bleeding\[[@B59]\].

Another study showed that SBADs, in presence of simultaneous angiodysplasias in other segments of the digestive tract (colon or stomach), are 4 times more likely to have a bleeding recurrence in one year after diagnosis\[[@B60]\]. SBADs were the cause of severe visible bleeding in 35% of cases\[[@B58]\].

CLASSIFICATION OF GIADs
=======================

Based on the endoscopic characteristics determined with VCE or DAE, SBADs may be classified in several types, possibly related with different extent of bleeding causality and bleeding recurrence (Table [2](#T2){ref-type="table"}).

###### 

Stratification of small bowel angiodysplasias based on endoscopic characteristics by video capsule endoscopy or device-assisted enteroscopy, clinical manifestations, bleeding causality and hemorrhagic recurrence probability (García-Compeán D et al)

  **Type**     **Endoscopic characteristics**                                                                       **Bleeding causality**   **Clinical manifestations**                                                                         **Bleeding recurrence probability**
  ------------ ---------------------------------------------------------------------------------------------------- ------------------------ --------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------
  **Type 1**   Punctuated or patchy lesions with non-pulsatile active bleeding                                      Certain                  Overt bleeding; high frequency of hemodynamic instability                                           Very high, without hemostatic treatment
  **Type 2**   Non-actively bleeding lesion; stigmata of hemorrhage (ulcer, adherent clot, digested blood debris)   High                     Frequently overt bleeding; lower frequency of hemodynamic instability than Type 1 lesions           Highly likely
  **Type 3**   Bright red spots; typical images                                                                     Moderate or mild         Overt or occult bleeding; low or null frequency of hemodynamic instability Iron deficiency anemia   Moderate rate; frequently IDA is dependent on iron supplements or blood transfusion
  **Type 4**   Pale red spots                                                                                       Low or null              Generally occult bleeding Chronic IDA; extra digestive cause of bleeding should be ruled out        When other sources of bleeding have been excluded, re-bleeding is low

IDA: Iron deficient anemia.

Type 1
------

Punctuate or patchy lesions with non-pulsatile active bleeding (which correspond to type 1a and 1b lesions of Yano-Yamamoto classification)\[[@B61]\] (Figure [2A](#F2){ref-type="fig"}). Patients may have hemodynamic instability and overt GIB. The bleeding recurrence may be very high in the absence of a hemostatic treatment.

![Endoscopic characteristics of small bowel angiodysplasias by video capsule endoscopy. A: Patchy lesion with non-pulsatile active bleeding (arrow) (Type 1 lesion); B: Non-bleeding lesion with central excavated ulcer (circle) (Type 2 lesion); C: Bright red patchy spot (arrow) (Type 3 lesion); D: Pale red spot (arrow) (Type 4 lesion). (García-Compeán D et al).](WJG-25-2549-g002){#F2}

Type 2
------

Non-actively bleeding lesions showing bleeding stigmata (adherent clot, ulceration or digested blood debris)\[[@B62]\] (Figure [2B](#F2){ref-type="fig"}). Patients may be hemodynamically stable and may present overt bleeding. Bleeding causality is highly probable and the bleeding recurrence may be high.

Type 3
------

Bright-red color patchy spots due to intense vascular congestion (Figure [2C](#F2){ref-type="fig"}). In the absence of other sources of bleeding, it is moderately likely that such lesions may be the cause of bleeding. Patients with this type of lesions may have occult or overt bleeding in similar proportions and moderate frequency of bleeding recurrence leading to blood transfusion or intravenous iron infusions-dependent anemia.

Type 4
------

Pale-red color patchy spots. These lesions are sometimes difficult to discern from erythema or artefacts in VCE studies (Figure [2D](#F2){ref-type="fig"}). Patients have iron deficiency anemia due to occult bleeding more frequently than overt bleeding. However, in some cases, anemia may be dependent on intravenous iron infusions or blood transfusions. These lesions have a low probability of being responsible of GIB. Therefore, any other source of digestive or extradigestive bleeding should be ruled out by measuring serum iron levels, screening fecal occult blood by the immunological test or a hematologic evaluation. The frequency of bleeding recurrence may be the lowest compared to the other type of lesions.

In non-actively bleeding lesions (types 2 to 4), the influence of the number and extent of lesions on bleeding causality and bleeding recurrence rate is unknown. The stratification of GIADs in combination with the presence or absence of comorbidities and with the concomitant use of pharmacologic anticoagulant agents may be helpful for selecting patients in whom, aggressive hemostatic invasive procedures (radiologic, endoscopic or surgical treatment), long-term prophylactic pharmacological therapy or only clinical observation must be prescribed.

TREATMENT
=========

Bleeding SBADs are more difficult to treat than gastric or colonic angiodysplasias due to their inaccessibility. GIB due to angiodysplasias is a frequent therapy challenge, no treatment guidelines are currently available, and so there is a high variability in the management of these patients\[[@B63],[@B64]\].

There are three treatment modalities: (1) Hemostatic; (2) Prophylactic; and (3) Rescue therapy. The former is applied to patients in whom continuous or intermittent persistent-active bleeding has been demonstrated and who frequently have hemodynamic instability, such condition is observed in around 10% of cases\[[@B65]\]. Prophylactic treatment aims to prevent bleeding recurrence in a long-term and rescue treatment is used when other modalities have failed. Whichever the treatment used, it is mandatory to stop the use of antithrombotic, antiaggregant or anticoagulant drugs.

Hemostatic treatment
--------------------

**Selective embolization by angiography:** This procedure has a high hemostatic effectiveness from 80% to 90%\[[@B66]-[@B68]\]. It is performed by selective catheterization of the vessel nourishing the bleeding lesion and subsequent injection of embolizing agents\[[@B69]\] (Figure [3](#F3){ref-type="fig"}). The most commonly used agents are biodegradable sponges and microcoils. This procedure is associated with complications in 5% to 9% of cases, of which 2% are severe\[[@B70],[@B71]\] and include hematomas, bowel infarction, arterial dissection, thrombosis, and pseudoaneurysms. Although this procedure has more complications than endoscopic therapy, it is more frequently used in patients with actively bleeding SBADs due to their inaccessibility. However, it is a complex procedure, which requires special technical equipment and highly trained operators in endovascular radiology.

![Selective embolization of small bowel vascular bleeding lesion by angiography. A: Selective catheterization of jejunal branch of superior mesenteric artery revealed a bleeding angiodysplasia (arrow); B: Super selective catheterization of bleeding-vessel using micro catheter; C: Angiogram after embolization revealed complete disappearance of active bleeding (arrow).](WJG-25-2549-g003){#F3}

**Endoscopic treatment:** It consists of the direct coagulation of the vascular lesions with several methods of which, the most used and clinically evaluated, is the argon plasma coagulation (APC)\[[@B72]-[@B75]\]. This procedure uses a mixture of electric current and argon gas that is applied through a non-contact endoscopic probe to the vascular lesion (Figure [4](#F4){ref-type="fig"}). This method has low penetration in the mucosa thus, the risks of perforation are quite low\[[@B75]\]. Other endoscopic contact-probe methods such as monopolar electrocoagulation (Heat Probe, Olympus, Japan) and bipolar electrocoagulation (Gold Probe, Boston Scientific) as well as photo coagulation with Nd:YAG (Neodymium: Yttrium- Aluminium-Garnet) and Argon Laser have been used for long time\[[@B76]-[@B79]\]. The endoscopic contact-probe methods such as electrocoagulation and laser photocoagulation techniques have similar hemostatic effectiveness compared to APC for bleeding GIADs\[[@B80]\], conversely, they have higher incidence of perforation particularly when they are used in the colon, where intestinal thin walls are present. Laser photocoagulation is a high cost technique that requires specialist expertise to deliver the treatment\[[@B81]\].

![Treatment of actively bleeding angiodysplasia (Type 1) in gastric fundus with argon plasma coagulation. A: Before coagulation; B: During coagulation, note the jet of ionized argon gas from the probe without contact with the vascular lesion (arrow); C: After coagulation (García-Compeán D et al).](WJG-25-2549-g004){#F4}

Hemoclipping\[[@B82]-[@B83]\] and multiple endoscopic band ligation\[[@B84],[@B85]\] have been reported to be effective as hemostatic therapy of bleeding vascular lesions. Nevertheless, reports are anecdotal with low number of patients; therefore, these techniques may be only used in selected cases, probably as rescue therapy. In conclusion, the first line recommended endoscopic treatment for bleeding GIADs is APC\[[@B86]\].

Endoscopic therapy is indicated for patients with few vascular lesions confined to one digestive tract segment and accessible to the endoscope. It has similar hemostatic effectiveness to that observed in selective angiographic embolization; however, bleeding recurrences are very frequent\[[@B33]\]. In a study of 183 with GIADs patients who underwent endoscopic treatment, there was a one-year bleeding recurrence rate of 34.5%, while recurrence rate at 2 years or more was 42% to 60%\[[@B74],[@B87],[@B88]\]. In a systematic review of 24 articles involving 490 patients with GIADs treated with endoscopic therapy, the bleeding recurrence rate was similar to that observed in patients without treatment (42.7% *vs* 49.2%)\[[@B89]\].

The complication rate of endoscopic therapy is lower than that observed in selective embolization by angiography (1.7%), with intestinal perforation being the most frequent one. Sub mucosal saline injection (with or without adrenaline) to form a fluid cushion in the colon before APC therapy, has been demonstrated to be effective for reducing this complication\[[@B90],[@B91]\].

Explosion of colonic gas is a rare complication that has been observed with the use of APC and electrocoagulation techniques. It is thought to be secondary to accumulation of combustible gases in the colon due to poor bowel preparation. So, a full colonic cleansing with oral purgatives is highly recommended before performing these techniques\[[@B92],[@B93]\]. The results in the treatment of the SBADs are poorer than those from the colon, with a higher bleeding recurrence rate being observed (78%)\[[@B59]\].

The high recurrence of bleeding in GIADs patients after endoscopic treatment could be due to the presence of untreated lesions, not endoscopically detected (particularly in small bowel) or the neoformation of lesions. Due to the long-term ineffectiveness of endoscopic therapy, we think that it should be followed with a long-term prophylactic pharmacological treatment or it can be performed "on demand", when bleeding recurrences occur\[[@B94]\]. In this context, combination therapy (endoscopic or radiological as hemostatic methods followed by pharmacological treatment as prophylactic therapy) has not been systematically evaluated. In a study with 52 patients with bleeding GIADs, treatment with APC followed by monthly ad-ministration of lanreotide during one year, proved to be more effective than isolated endoscopic treatment since it significantly reduced the recurrence of bleeding and the long-term requirements for blood transfusions\[[@B95]\].

Prophylactic treatment
----------------------

Currently, highly effective prophylactic treatment for GIADs is not available for clinical use. Nevertheless, several pharmacological agents have been evaluated recently; some of them have shown promising results (Table [3](#T3){ref-type="table"}).

###### 

Prospective and controlled trials evaluating the efficacy of hormonal therapy, somatostatin analogues and thalidomide in patients with recurrent bleeding due to gastrointestinal angiodysplasias confirmed by endoscopy

  **Author (yr)**                    **Design**              ***n***          **Treatment**                                                         **Follow--up (mo)**   **Results**
  ---------------------------------- ----------------------- ---------------- --------------------------------------------------------------------- --------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  Hormonal therapy                                                                                                                                                        
  Van Cutsem et al\[[@B98]\], 1990   DB, Cr Ov, Rx *vs* P,   10               Oral Ethinyloestradiol and norethisterone for 6 mo                    6                     Significant reduction of transfusion requirement in Rx patients *vs* controls (*P* \< 0.003). Non-significant side effects in treated patients
  Barkin and Ross\[[@B99]\],1998     Cohort                  25               Oral Mestranol and norethynodrel or norethinidrone                    18 (1-52)             None patients rebled during Rx. Side effects in 44% of patients
  Junquera et al\[[@B100]\], 2001    R, DB, Rx *vs* P        Rx = 33 P = 35   Oral Norethisterone and ethinylstradiol for 1-2 yr                    12 (12-36)            Bleeding recurrence: Rx = 39% *vs* P = 46%; *P* = NS
  Somatostatin analogues                                                                                                                                                  
  Nardone et al\[[@B106]\], 1999     Cohort                  17               SC Octreotide 100 µg/8 h for 6 mo                                     12                    Rates of complete, partial and non-response were 59%, 23% and 18% respectively; non-significant side effects
  Junquera et al\[[@B107]\], 2007    Cohort, Rx *vs* P       Rx = 32 P = 38   SC Octreotide 50 µg/12 h for 12-24 mo                                 13 (12-36)            Bleeding recurrence: Rx = 23% *vs* P = 48% (*P* = 0.04); major adverse effects: Rx = 3.1% *vs* P = 2.6%
  Scaglione et al\[[@B111]\], 2007   Cohort                  13               IM Lanreotide 10 mg/mo for 12 mo                                      33 (12-60)            Rates of complete, partial and non-response were 70% and 23% respectively; non-significant side effects were observed
  Molina et al\[[@B111]\], 2009      Cohort                  11               IM Lanreotide 20 mg/mo                                                15 (5-48)             Patients with serious comorbidities; treatment reduced transfusion requirements and bleeding related hospitalizations
  Bon et al\[[@B113]\], 2012         Cohort                  15               IM Lanreotide 20 mg/mo for 12 mo                                      14 (10-36)            Rx significantly reduced bleeding recurrences, transfusion requirements and increased serum Hb levels; side effect were rare
  Holleran et al\[[@B108]\], 2016    Cohort                  24               IM Lanreotide 20 mg/mo for 3 mo                                       8 (3-17)              Rates of complete, partial and non-response were 70%, 20% and 10% respectively; adverse events: 30%
  Thalidomide                                                                                                                                                             
  Ge et al\[[@B121]\], 2011          Cohorts Rx *vs* C       R = 28 C: 27     Oral thalidomide 100 mg/day for 4 mo; oral iron 400 mg/day for 4 mo   39 (8-52)             Rate of response; Rx = 71.4 *vs* 3.7%; non-significant side effects
  Garrido et al\[[@B119]\], 2012     Cohort                  12               Oral 200 mg/day for 4 mo                                              4                     Increase of serum Hb levels; severe side effects requiring Rx discontinuation in 17%

R: Randomized; DB: Double blind; Cr Ov: cross over; Rx: Treatment; P: Placebo; C: Controls; IM: Intramuscular; SC: Subcutaneous; NS: Non-significant.

**Hormonal drugs:** This therapy (a mixture of estrogens and progestogens) began to be used in the 80s. Initial studies reported a favorable effect on the recurrence of bleeding\[[@B96]-[@B99]\]. However, they were retrospective and non-controlled studies with few patients. A good quality, multicenter, prospective, controlled, double-blind, placebo-compared study involving 72 patients with acute and chronic bleeding treated with hormonal drugs for 1 to 3 years showed no therapeutic benefit\[[@B100]\]. This study was key to abandon the use of these drugs for GIADs therapy.

**Somatostatin analogues:** In the 90s, octreotide and lanreotide began to be used in the treatment of bleeding GIADs. These drugs are somatostatin analogues and their mechanism of action on GIADs is probably multiple. It is suggested that they have a hemodynamic effect on the splanchnic circulation; they inhibit angiogenesis-promoter chemical-factors such as VEGF, b-FGF and IGF-1 k. In addition, these drugs may stimulate relaxation of intestinal smooth muscle thus reducing the chronic obstruction of sub mucosal veins\[[@B101],[@B102]\].

Initially, a beneficial effect of subcutaneous octreotide administration on bleeding recurrence was reported in isolated cases or short series of patients with bleeding GIADs refractory to other treatments\[[@B103]-[@B105]\]. A study involving 17 patients, who received 300 µg/day for 6 mo, showed a reduced requirement for treatment of anemia in 82.3% of the patients\[[@B106]\]. Another long-term placebo-compared study involving 70 patients treated with 100 µg daily for 1 to 2 years demonstrated a 1- and 2-year effectiveness of 77 and 68% *vs* 55 and 36% of the control group, respectively (*P* = 0.03). In this study, octreotide therapy and the number of previous episodes of bleeding were independent predictors of efficacy\[[@B107]\].

In the 2000s, the first studies with lanreotide (which is a drug used in the treatment of acromegaly and the symptoms caused by carcinoid syndrome) were published. The monthly parenteral administration of this drug facilitates the patient\'s treatment compliance. In three publications, monthly administration of 10 to 20-mg to patients with bleeding GIADs, showed a beneficial effect of 75% to 90% of cases. This effectiveness was measured by reduction of blood transfusion and iron infusions requirement as well as bleeding episodes and bleeding-related hospitalizations reduction. However, almost all the studies published to date are retrospective, with a small number of patients, and non-comparative\[[@B108]-[@B113]\]. A meta-analysis and systematic review of 24 studies involving 831 individuals with GIADs showed that octreotide and lanreotide treatment is more effective than endoscopic therapy in reducing recurrence of bleeding in the short and long term\[[@B72]\].

Finally, treatment with somatostatin analogues is associated with a low frequency of adverse effects. Most of them are digestive (diarrhea, abdominal pain) and are tolerable, rarely necessitating interruption of treatment. However, these drugs should be cautiously used in patients with asymptomatic cholecystolithiasis or difficult-to-treat diabetes mellitus\[[@B114]\].

**Thalidomide:** A series of isolated reports on the beneficial effect of thalidomide in the treatment and prevention of bleeding recurrence of GIADs\[[@B115]-[@B119]\] has been recently published. It is thought that thalidomide acts by inhibiting angiogenesis by suppressing VEGF\[[@B120]\]. In a randomized controlled trial involving 52 patients who received orally 100 mg daily of thalidomide *vs* 400 mg of iron for 4 mo, it was observed that the therapeutic response, which was measured by a 50% reduction in bleeding episodes during one year, was significantly higher in the patients who received the drug (71% *vs* 4%). Thalidomide reduced the number of transfusion-dependent patients (11 *vs* 48%) and re-hospitalizations due to bleeding (39% *vs* 100%). However, patients treated with thalidomide showed more adverse reactions than controls (71.4% *vs* 33.3%, respectively) of which fatigue, constipation, dizziness and peripheral edema were the most frequent\[[@B121]\].

In conclusion, prophylactic therapy with somatostatin analogues or thalidomide seems to be an effective alternative of GIADs. However, prospective, controlled, randomized studies with a sufficient number of patients are required in order to confirm this issue. A cost-benefit ratio assessment should be included in these studies, since these are high-cost drugs at present, especially somatostatin analogues.

Rescue therapy
--------------

This therapy is used in patients with acute bleeding or recurrent chronic bleeding refractory to initially administered measures. There is no defined rescue treatment strategy, so radiological, endoscopic and pharmacological treatments have been sequentially or combinedly used with this aim\[[@B75],[@B122],[@B123]\]. Notwithstanding, the most effective rescue treatment is surgical resection\[[@B124]\]. However, it is associated with high perioperative morbidity and mortality rates of 23% and 12%, respectively\[[@B125]\], since most patients with GIADs are of advanced age and frequently suffer diverse comorbidities. After the introduction of technically advanced non-surgical methods for GIADs, as those previously described in this review, the number of patients undergoing surgery has significantly reduced. Nonetheless, surgery remains a valid therapeutic alternative, which must be considered when the other therapeutic modalities have failed, in patients with acceptable operative risk, who have focalized lesions in any segment of the digestive tract and bleeding causality of vascular lesions is confirmed\[[@B126]\]. The Figure [5](#F5){ref-type="fig"} describe a practical guide for the treatment of GIADs based on the place where they are located, the clinical manifestations and the endoscopic type of lesions.

![Practical guide for treatment of gastrointestinal angiodysplasias based on their localization, clinical manifestations and endoscopic type lesion. Small bowel angiodysplasias are separately considered due to their difficult accessibility. ^1^Hemostatic treatment; ^2^Prophylactic treatment; ^3^Consider adequate surgical risk patients with focalized lesions; ^4^Type 1 (actively bleeding) and Type 2 (with bleeding stigmata); ^5^Type 3 (bright red spots); ^6^Alternate use of procedures.](WJG-25-2549-g005){#F5}

FUTURE OF RESEARCH
==================

The genesis of GIADs is closely linked to angiogenesis. This is a complex process, in which multiple chemical mediators participate \[VEGF, endoglin, Ang-1, Ang-2, platelet derived growth factor, and tumor necrosis factor alpha (TNFα)\]. An increase in VEGF has been found in response to tissue hypoxemia\[[@B30]\]. Endoglin is a trans-membranal glycoprotein that is strongly expressed in endothelial cells during the process of angiogenesis\[[@B127]\]. Ang-2, (which is a member of the angiopoietin family), rises rapidly in response to angiogenic stimuli and it is thought to induce the formation of immature and unstable blood vessels\[[@B128]\]. vWF stores in endothelial cells and regulates the release of Ang-2 and integrin by a complex interaction with the VEGF receptor\[[@B32]\].

A recently published study with GIAD patients showed a significantly lower serum of Ang-1/Ang-2 ratio compared to subjects without GIADs. In angiodysplastic tissue, significant differences in the messenger RNA expression of Ang-1 and Ang-2 and its Tyrosine kinase receptor 2 were found\[[@B32]\]. Another recent prospective study showed high Ang-2 levels and low tendency of Ang-1 and TNF-α levels in patients with SBADs compared to individuals who had bleeding from other causes\[[@B129]\].

Despite the progress achieved in this field, the clinical use of chemical markers of angiogenesis as diagnostic tools is still in early stage. However, it is a promising area of research. Biological markers of angiogenesis may be useful tools for evaluation of severity of lesions, prediction of bleeding recurrence, and therapeutic response. It must be remembered that the somatostatin analogues and thalidomide have an anti-angiogenic effect. The deeper knowledge of the pathogeneses of GIADs, particularly in relation to angiogenesis, will possibly contribute to the identification of more highly specific angiogenesis mediators and stimulate the development of highly selective antagonist agents directed against specific targets in order to improve therapeutic results.
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